VANCOUVER, British Columbia, June 28, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTC BB:TPIM.OB - News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key Transporter Associated with Antigen Processing (TAP) technology platform and patents. All financial terms with The University of British Columbia have been met. Technology assignment and transfer is expected to be completed in the next week.
